General Information of Drug (ID: DMAQX4K)

Drug Name
(S)-tert-butyl 1-oxohexan-2-ylcarbamate
Synonyms
CHEMBL96875; ((S)-1-Formyl-pentyl)-carbamic acid tert-butyl ester; BML-244; (S)-tert-butyl 1-oxohexan-2-ylcarbamate; Carbamic acid, [(1S)-1-formylpentyl]-, 1,1-dimethylethyl ester; SCHEMBL3285479; CTK0G6629; OBMGXPJNZKYOQY-VIFPVBQESA-N; ZINC13588585; BDBM50137790; AKOS030572335; tert-butyl(1S)-1-formylpentylcarbamate; CCG-207873; 2(S)-(tert-Butoxycarbonylamino)hexanal; tert-butyl (1S)-1-formylpentylcarbamate; (2S)-2-(tert-Butoxycarbonylamino)hexanal; (S)-2-(tert-butoxycarbonylamino)-5-methylpentanal
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 215.29
Logarithm of the Partition Coefficient (xlogp) 2.3
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 3
Chemical Identifiers
Formula
C11H21NO3
IUPAC Name
tert-butyl N-[(2S)-1-oxohexan-2-yl]carbamate
Canonical SMILES
CCCC[C@@H](C=O)NC(=O)OC(C)(C)C
InChI
InChI=1S/C11H21NO3/c1-5-6-7-9(8-13)12-10(14)15-11(2,3)4/h8-9H,5-7H2,1-4H3,(H,12,14)/t9-/m0/s1
InChIKey
OBMGXPJNZKYOQY-VIFPVBQESA-N
Cross-matching ID
PubChem CID
10420833
TTD ID
D0T7QF

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cathepsin K (CTSK) TTDZN01 CATK_HUMAN Inhibitor [1]
Cathepsin L (CTSL) TT36ETB CATL1_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cathepsin K (CTSK) DTT CTSK 2.85E-01 -1.14 -2.61
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors Bioorg Med Chem Lett. 2006 Feb 15;16(4):978-83.